Quintrigen
p53 reactivation
YEDA, the technology holding company of Israel's Weizmann Institute of Science, has established Quintrigen, a local joint venture. This collaboration marks a significant step towards fostering technological innovation and advancement, focusing on cutting-edge research and technology commercialization
Restoring p53: The Key to Revolutionary Cancer Therapy
Damage to the p53 gene is found in over 50% of cancers. Restoring p53 could become an innovative cancer treatment.
Tackling fundamental problems underlying cell proliferation and oncogenesis will provide an
effective solution to develop an innovative, life-saving cancer therapy.
* Arrested cell proliferation
* Death of cancer cells
* Sensitiztion of refractory cancers
Restore p53's cancer suppression function using specific peptides.
- Screen promising peptide candidates using phage display libraries
- Synthesize peptides based on consensus motifs identified through bioinformatics
- Conduct ELISA-based semi-high throughput screening
- Lead peptide selection